Navigation Links
Discovery Labs Reports Third Quarter 2012 Financial Results

WARRINGTON, Pa., Nov. 8, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reported financial results for the third quarter ended September 30, 2012.

  • For the third quarter of 2012, the Company reported an operating loss of $10.0 million with net cash outflows of $9.9 million.  As of September 30, 2012, the Company had cash and cash equivalents of $36.1 million.
  • The Company has deployed its newly-hired field force to focus on the near-term objective of securing hospital formulary acceptance for SURFAXIN® and adoption of AFECTAIR®.
  • The Company anticipates product availability for SURFAXIN early in the second quarter of 2013 and its initial AFECTAIR device for infants in December 2012.
  • The Company remains focused on the development of AEROSURF® and is on track for the potential initiation of a phase 2 clinical trial in the second half of 2013.  To prepare for this effort, the Company plans to complete development and validation of its commercial scale manufacturing process for its lyophilized KL4 surfactant and a 'clinic ready' capillary aerosol generator (CAG) device by mid-2013.
  • For the quarter ended September 30, 2012, the Company reported a net loss of $13.3 million ($0.31 per share) on 43.4 million weighted-average common shares outstanding, compared to a net loss of $4.8 million ($0.20 per share) on 24.1 million weighted-average common shares outstanding for the comparable period in 2011.  Included in the net loss is the change in fair value of certain common stock warrants that are classified as derivative liabilities, resulting in non-cash expense of $3.3 million for quarter ended September 30, 2012 and non-cash income of $1.4 million for the quarter ended September 30, 2011.

    The Company reported an operating loss of $10.0 million for the quarter ended September 30, 2012 compared to an operating loss of $6.2 million for the comparable period in 2011.  The increase in the operating loss is primarily due to investments in the Company's specialty commercial and medical affairs organizations, including a field sales force, national accounts team and medical science liaison team. These teams are focused primarily on gaining hospital formulary acceptance for SURFAXIN and adoption of AFECTAIR.

    Net cash outflows for the quarter ended September 30, 2012 were $9.9 million.  For the fourth quarter of 2012, the Company anticipates operating cash outflows of $9.5 million, before taking into account financing activities.

    As of September 30, 2012, the Company had cash and cash equivalents of $36.1 million.  The Company had 43.5 million and 24.6 million shares of common stock outstanding as of September 30, 2012 and December 31, 2011, respectively.

    As of September 30, 2012, the Company reported a common stock warrant liability of $11.9 million, of which $11.4 million is related to five-year warrants issued in February 2011.  These warrants have been classified as derivative liabilities in accordance with generally accepted accounting principles because they contain anti-dilution provisions that adjust the exercise price of the warrants in certain circumstances.  The remaining balance of $0.5 million is related to registered warrants issued in May 2009 and February 2010.  These warrants state that, in the event a related registration statement or an exemption from registration is not available for the issuance or resale of the warrant shares upon exercise of the warrants, the holder may exercise the warrants on a cashless basis.  However, regardless of the remote likelihood that an event would result in cash settlement, the warrants have been classified as derivative liabilities in accordance with generally accepted accounting principles because they do not expressly state that there is no circumstance in which the Company will be required to settle the warrants in cash.Readers are referred to, and encouraged to read in their entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 to be filed with the Securities and Exchange Commission, which includes further detail on the above-referenced transactions and the Company's business plans and operations, financial condition and results of operations.

    Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care.  Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.  For more information, please visit our website at

    Forward-Looking Statements
    To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results, including projections of future cash balances and anticipated cash outflows, to differ materially from the statements made.  Examples of such risks and uncertainties are: risks relating to Discovery Labs' efforts to successfully commercialize SURFAXIN and AFECTAIR, including: (i) whether Discovery Labs' products will meet the requirements to be included in the hospitals' purchasing lists of approved drug products, medical devices and equipment, (ii) whether Discovery Labs' products will gain market acceptance and healthcare professionals will recognize the perceived advantages over the currently available products, (iii) whether Discovery Labs will succeed in introducing its products using its own commercial and medical affairs organizations; (iv) whether Discovery Labs will be successful in completing development of, and introducing, its planned second vial size for SURFAXIN and follow-on AFECTAIR devices; and (v) even if Discovery Labs is successful in commercializing its products, whether its products will be profitable and whether the revenues generated will be sufficient to fund Discovery Labs' research and development activities and support its operations; risks that Discovery Labs may be unable in a timely manner, if at all, (i) to identify potential strategic partners or collaborators to support development of its products and, if approved, commercialize its products in markets outside the U.S., (ii) to access its committed equity financing facility (CEFF), or (iii) to raise additional capital to fund its activities, or that additional financings could result in substantial equity dilution; risks related to Discovery Labs' research and development activities, including time-consuming and expensive pre-clinical studies, clinical trials, which may be subject to potentially significant delays or regulatory holds, or fail, and the need for sophisticated and extensive analytical methodologies; risks related to technology transfers to contract manufacturers and problems, or delays encountered by Discovery Labs, its contract manufacturers or suppliers in manufacturing drug products, drug substances and other materials and ventilator circuit/patient interface connectors and CAG devices on a timely basis and in an amount sufficient to support Discovery Labs' development efforts and, if approved, commercialization; risks relating to the rigorous regulatory requirements required for approval of any drug, drug-device combination or medical device products that Discovery Labs may develop, including that: (a) the U.S. Food and Drug Administration (FDA) or other regulatory authorities may not agree with Discovery Labs on matters raised during regulatory reviews or may require Discovery Labs to conduct significant additional activities to potentially gain approval of its product candidates, if ever, (b) the FDA or other regulatory authorities may not accept or may withhold or delay consideration of any of Discovery Labs' applications, or may not approve or may limit approval of Discovery Labs' products to particular indications or impose unanticipated label limitations, and (c) changes in the national or international political and regulatory environment may make it more difficult to gain FDA or other regulatory approval; the risk that Discovery Labs or its strategic partners or collaborators will not be able to retain, or attract, qualified personnel; the risk that Discovery Labs will be unable to maintain compliance with The Nasdaq Capital Market listing requirements, which could cause the price of Discovery Labs' common stock to decline; risks that Discovery Labs may be unable to maintain and protect the patents and licenses related to its products, or other companies may develop competing therapies and/or technologies, or health care reform may adversely affect Discovery Labs; risks of legal proceedings, including securities actions and product liability claims; risks relating to health care reform; and other risks and uncertainties described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.Condensed Consolidated Statement of Operations
    (in thousands, except per share data) 

    Three Months EndedNine Months EndedSeptember 30,September 30(unaudited)(unaudited)2012201120122011Revenue from collaborative arrangement and
    582Operating expenses: (1)Research and development5,7433,98115,48213,216Selling, general and administrative4,2552,1899,9125,975Total expenses9,9986,17025,39419,191Operating loss(9,998)(6,170)(25,394)(18,609)Change in fair value of common stock warrant liability (1)(3,309)1,422(5,063)1,957Other income / (expense), net(39)(3)(43)(12)Net loss $
    (16,664)Net loss per common share$
    (0.75)Weighted avg. common shares outstanding43,44424,10638,06122,104(1) Material non-cash items include the change in fair value of certain outstanding warrants accounted for as derivative liabilities, and in operating expenses, depreciation and stock-based compensation. For the three and nine months ended September 30, 2012, the charges for depreciation and stock-based compensation were $0.8 million ($0.4 million in R&D and $0.4 million in S,G&A) and $2.1 million ($1.2 million in R&D and $0.9 million in S,G&A), respectively. For the three and nine months ended September 30, 2011, the charges for depreciation and stock-based compensation were $0.5 million ($0.4 million in R&D and $0.1 million in S,G&A) and $1.5 million ($1.1 million in R&D and $0.4 million in S,G&A), respectively.  

    Condensed Consolidated Balance Sheets
    (in thousands)September 30,December 31,20122011ASSETS(Unaudited)Current Assets:Cash and cash equivalents

    ,189Prepaid expenses and other current assets

    1,293442Total current assets

    37,35710,631Property and equipment, net

    1,9952,293Other assets

    400400Total Assets

    3,324LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    ,111Accrued expenses

    3,6652,972Common stock warrant liability

    11,9236,996Equipment loan and capitalized leases, current portion

    6868Total Current Liabilities

    15,86411,147Long-Term Liabilities:Equipment loan  and capitalized leases, non-current portion & other liabilities

    837913Total Liabilities

    16,70112,060Stockholders' Equity

    23,0511,264Total Liabilities and Stockholders' Equity


    SOURCE Discovery Laboratories, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
    2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
    3. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
    4. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
    5. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
    6. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
    7. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
    8. AMRI Further Expands Discovery Capabilities in India
    9. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
    10. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
    11. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
    Post Your Comments:
    (Date:10/9/2015)... , October 9, 2015 ... die sich einer Kolonoskopie im Rahmen eines ... unterziehen. Die NOCT-Studie bewertete auch die Compliance, ... --> ® ) an erwachsenen Patienten ... eines Screenings, einer beobachtenden oder einer diagnostischen ...
    (Date:10/9/2015)... , October 9, 2015 ... (OTCQB: CNBX) has announced its execution of an Intellectual Property ... Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, related party, ... --> --> These ... of the Company, whereby the Research and Development components ...
    (Date:10/9/2015)... India , October 9, 2015 ... --> The report ... market and overall status of the ... of guidance and direction for companies ... . ...
    Breaking Medicine Technology:
    ... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
    ... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
    Cached Medicine Technology:
    (Date:10/10/2015)... ... ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, 2015 ... Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be featuring ... and consumers to potentially reduce the chance of error. The report suggests that most ...
    (Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic Foundation ... Graduate Medical Education J. Michael Finley, DO, as the recipient of the 2015 ... his impact on graduate medical education opportunities for osteopathic residents, and his dedication ...
    (Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is ... – just in time for the cold and flu season, which the Center for ... the U.S., the real start of cold/flu season is the start of the school ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington Beach ... system that uses clear, plastic aligners. This alternative to braces has become wildly ... allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so ...
    (Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Asthma ... the US Centers for Disease Control and Prevention (CDC) to improve the knowledge and ... that AAFA has been awarded a project by the CDC and allows AAFA to ...
    Breaking Medicine News(10 mins):
    ... better diagnosis and drug treatments, study says , , WEDNESDAY, ... most common form of mental retardation -- called nonsyndromic ... that may contribute to the condition, new research finds. ... occurs during development of the child and is not ...
    ... virus strikes healthy kids, and it affects more youngsters than ... It,s called respiratory syncytial virus (RSV), a childhood infection that,s ... and one of every 38 emergency room trips, a new ... for inpatient hospital stays for one out of every 334 ...
    ... is a statement by Matthew L. Myers, President, ... and President Obama today are delivering a historic ... increasing federal tobacco taxes, including a 62-cent increase ... Children,s Health Insurance Program (SCHIP). This legislation ...
    ... Feb. 4 , WHAT: , ... event, with members of the cast,of Broadway,s Tony Award-winning best ... February 6, 2009 , WHO: , ... compelling stories of women making,heart-healthy choices and inspiring others with ...
    ... seeks new ways to prevent and treat chronic diseases such ... be conducted on the benefits of certain foods in reducing ... often cited as being high in antioxidants, which have the ... within the body, reducing the risk of cancer and other ...
    ... Feb. 4 Erik Olson, director of chemical and food ... the following statement today in response to the introduction of ... , , "In the midst of ... Safety Modernization Act (FSMA) could not be more timely. The ...
    Cached Medicine News:
    2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
    Pocket-sized instrument with 2.5X magnification....
    Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
    Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.5V halogen source....
    Medicine Products: